Infections associated with diabetic-care devices

Diabetes Metab Syndr. 2021 Mar-Apr;15(2):519-524. doi: 10.1016/j.dsx.2021.02.023. Epub 2021 Feb 19.

Abstract

Background and aims: There are more than 463 million people living with diabetes with this number expected to increase to 700 million people by 2045. Diabetes is a risk factor for patients developing various comorbidities including, but not limited to, diabetic neuropathy, retinopathy, chronic kidney disease, vascular impediments, and infections. Due to the continuous invasiveness of monitoring and/or treatment of this disease, site for infections are elevated.

Methods: Information was primarily gathered by employing various PubMed scholarly articles for real-world examples in addition to data extraction from supplementary manuscripts. Key search words employed were: diabetes, insulin site infection, lancing infections, insulin pump associated infections, and continuous glucose monitoring infections.

Results: Diabetic care devices used for blood glucose monitoring and insulin administration are an integral part of the disease management and/or treatment in various settings including patient homes, assisted living facilities, community centers, and hospitals. These invasive devices leave a diabetic patient with a small open wound which may get infected or aid in blood borne pathogen transmission. Since diabetes itself has a morbidity and mortality burden, it is important to also study complications arising from the management of diabetes.

Conclusion: Although cases exist of infections, either by pathogen transmission or direct inoculation of the prick site, these are a very small percentage and thus should not undermine the confidence in diabetes management. This review highlights the instances of these infections and where they most often occur.

Keywords: Continuous glucose monitoring; Diabetes mellitus; Infections; Insulin injection; Self-monitoring of blood glucose.

Publication types

  • Review

MeSH terms

  • Blood Glucose / metabolism
  • Blood Glucose Self-Monitoring / adverse effects
  • Blood Glucose Self-Monitoring / methods*
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / epidemiology*
  • Diabetes Mellitus, Type 1 / therapy
  • Diabetic Neuropathies / diagnosis
  • Diabetic Neuropathies / epidemiology*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Injection Site Reaction / diagnosis
  • Injection Site Reaction / epidemiology
  • Injection Site Reaction / therapy
  • Soft Tissue Infections / diagnosis
  • Soft Tissue Infections / epidemiology*
  • Soft Tissue Infections / therapy

Substances

  • Blood Glucose
  • Hypoglycemic Agents